{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:15:10Z","timestamp":1790039710510,"version":"4.0.1"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,20]]},"DOI":"10.18632\/oncotarget.13069","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T10:41:36Z","timestamp":1478256096000},"page":"84951-84964","source":"Crossref","is-referenced-by-count":35,"title":["PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors"],"prefix":"10.18632","volume":"7","author":[{"given":"Minghui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"},{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"},{"name":"Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, 300052, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bjc.2015.30","article-title":"Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study","volume":"112","author":"Emery","year":"2015","journal-title":"British Journal of Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC","volume":"3","author":"Karp","year":"2013","journal-title":"Cancer Discovery"},{"key":"3","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1038\/sj.bjc.6605401","article-title":"What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable&quest","volume":"101","author":"Coleman","year":"2009","journal-title":"British Journal of Cancer"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Camidge, Pao, Sequist. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Publishing Group. Nature Publishing Group. 2014; pp. 1\u20139.","DOI":"10.1038\/nrclinonc.2014.104"},{"key":"5","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations","volume":"31","author":"Kato","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"ArticlesErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Garrido","year":"2012","journal-title":"Lancet Oncology"},{"key":"7","doi-asserted-by":"crossref","first-page":"e0136155","DOI":"10.1371\/journal.pone.0136155","article-title":"Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Chellappan SP, editor","volume":"10","author":"Puri","year":"2015","journal-title":"PLoS ONE"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Planchard, Loriot, Andr\u00e9, Gobert, Auger, Lacroix, Soria. C. EGFR independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015; p. mdv319.","DOI":"10.1093\/annonc\/mdv319"},{"key":"9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Riely","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10","first-page":"27","article-title":"Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor","volume":"32","author":"Chen","year":"2012","journal-title":"Oncogene"},{"key":"11","doi-asserted-by":"crossref","unstructured":"C, B, Chakraborty, N, Ali, Zhu. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Sci Rep. 2014; p. 4.","DOI":"10.1038\/srep05868"},{"key":"12","first-page":"e1850","article-title":"Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer","volume":"6","author":"Eramo","year":"2015","journal-title":"Nature Publishing Group"},{"key":"13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","article-title":"Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI","volume":"89","author":"Ou","year":"2015","journal-title":"Lung Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Yu","year":"2007","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC","volume":"17","author":"Akhavanfard","year":"2010","journal-title":"Cancer Cell"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Qiu, Guo, Zhao, Wang, Zhang. Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Sci Rep. Nature Publishing Group. 2015; pp. 1\u20137.","DOI":"10.1038\/srep11317"},{"key":"17","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Xu","year":"2014","journal-title":"British Journal of Cancer"},{"key":"18","first-page":"877","article-title":"BRAFE600 in benign and malignant human tumours","volume":"27","author":"Peeper","year":"2007","journal-title":"Oncogene"},{"key":"19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2015.90","article-title":"Refining the treatment of NSCLC according to histological and molecular subtypes","volume":"12","author":"Giaccone","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"J\u00e4nne","year":"2013","journal-title":"Nature Medicine"},{"key":"21","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/srep02560","article-title":"IGF-1R\/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations","volume":"3","author":"Menendez","year":"2013","journal-title":"Sci Rep"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Jotte, Spigel. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med. 2015. n\/a-n\/a.","DOI":"10.1002\/cam4.506"},{"key":"23","first-page":"354","article-title":"[Drug resistance mechanism of non small cell lung cancer PC9\/AB2 cell line with acquired drug resistance to gefitinib]","volume":"33","author":"Ding","year":"2010","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18632\/genesandcancer.24","article-title":"CDK4\/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models","volume":"5","author":"Knudsen","year":"2014","journal-title":"Genes Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4161\/cc.21127","article-title":"CDK4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy","volume":"11","author":"Knudsen","year":"2012","journal-title":"Cell Cycle"},{"key":"26","first-page":"4885","article-title":"Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase","volume":"6","author":"Kris","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Ayeni, Politi, Goldberg. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clinical Cancer Research. American Association for Cancer Research. 2015. clincanres.1211.2015.","DOI":"10.1158\/1078-0432.CCR-15-1211"},{"key":"28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends-An Update","volume":"25","author":"Jemal","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1159\/000369526","article-title":"Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation","volume":"7","author":"Quoix","year":"2014","journal-title":"Case Rep Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","article-title":"Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor","volume":"10","author":"Heo","year":"2015","journal-title":"J Thorac Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/oncsis.2013.4","article-title":"A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop","volume":"2","author":"Heasley","year":"2013","journal-title":"Oncogenesis"},{"key":"32","first-page":"11","article-title":"Recurrent amplification in the 22q11 region in laryngeal squamous cell carcinoma results in overexpression of the CRKL but not the MAPK1 oncogene","volume":"8","author":"Szyfter","year":"2010","journal-title":"Cancer Biomark"},{"key":"33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.3995","article-title":"In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A\/p21, PTEN, AKT3 and TIMP2","volume":"227","author":"Croce","year":"2012","journal-title":"J Pathol"},{"key":"34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-24223-1_7","article-title":"Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update","volume":"893","author":"Ahsan","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"35","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Miller","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"37","first-page":"957437","article-title":"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer","volume":"2012","author":"Villalona","year":"2012","journal-title":"J Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/1535-7163.MCT-12-0562","article-title":"Cdk4\/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells","volume":"11","author":"Korc","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"39","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"McArthur","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"40","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Ginther","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"41","first-page":"4300","article-title":"Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)","volume":"62","author":"Harari","year":"2002","journal-title":"Cancer Research"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Sheppard. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. 2013; 19:5320\u20138.","DOI":"10.1158\/1078-0432.CCR-13-0259"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T14:05:31Z","timestamp":1596722731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":42,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12,20]]}},"alternative-id":["13069","27825114"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13069","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}